Aarey Drugs & Pharmaceuticals Limited
AREYDRG.BO
Bombay Stock Exchange61.59
INR
-2.16
- -
Aarey Drugs & Pharmaceuticals Limited
AREYDRG.BO
(Bombay Stock Exchange)
Recent
price
61.59
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Aarey Drugs & Pharmaceuticals Limited Aarey Drugs & Pharmaceuticals Limited engages in the manufacturing and trading of active pharmaceutical ingredients, pharmaceutical intermediates, specialty chemicals, and industrial solvents in India. The company produces bulk drugs including antibiotics and anti-inflammatory APIs such as metformin HCL, mefenamic acid, and doxophylline; intermediates like ortho para nitro anisole and 2 bromomethyl 1,3 dioxalane; fine and organic chemicals for pharmaceuticals, agriculture, and other sectors; as well as aromatic chemicals, chemical acids, chlor-alkalies, glycols, acetates, esters, chlorinated solvents, ketones, amines, and oleochemicals. It offers contract manufacturing services encompassing custom synthesis and toll manufacturing for pharmaceutical clients, alongside research and development for process innovation, quality control, GMP-certified production, and regulatory compliance support; its products serve pharmaceutical formulation manufacturers, merchant exporters, and diverse industrial applications globally from facilities in Tarapur, Maharashtra. Founded in 1990 and headquartered in Mumbai, India, with registered offices at E-34 MIDC Tarapur, Boisar, Thane District, the company operates primarily in the pharmaceuticals and chemicals sectors targeting domestic and international markets. Recent developments include a 10.48% rise in standalone net profit for the June 2025 quarter despite a sales decline, board approvals for fund raising initiatives such as rights issues and preferential allotments of equity shares and warrants in 2024-2025, an increase in authorized share capital from Rs 255 crore to Rs 355 crore, and scheduling of the 35th AGM on September 29, 2025, with ongoing quarterly results announcements and related party transaction approvals.